The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a ...

Novo Nordisk (CPSE:NOVO B) has quietly slipped over the past year, even as its diabetes and obesity franchise keeps growing. That disconnect between share performance and earnings momentum is where ...

If you are wondering whether Novo Nordisk is a rare bargain or a value trap at today's price, you are not alone. This breakdown will help you see what the market might be missing. The stock has ...

Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight ...

The partnership forged by Novo Nordisk (NVO) and Hims & Hers (HIMS) in April appeared to bring together two giant brands in the growing weight-loss market. It's why the sudden fallout less than two ...

Novo Nordisk A/S (NVO), though cheap at 13x forward earnings, is in my view a value trap, as growth is slowing and GLP-1 pricing pressures are capping revenue and profitability.

Former Novo Nordisk CSO Marcus Schindler on R&D leadership, pharma innovation, scientific discovery, AI, global talent, DEI, biotech, drug development strategy.

GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for ...

Novo Nordisk agreed to collaborate with Replicate Biosciences to develop potential new treatments for obesity, type 2 diabetes and other cardiometabolic diseases, as it grapples with mounting ...

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow ...

The primary aim of the trial was to determine whether semaglutide could slow the cognitive decline associated with Alzheimer's disease by at least 20%. Despite improvements in Alzheimer’s ...

Biotech Structure Therapeutics’ (GPCR) shares rallied 102.49% on Monday after mid-stage data for its obesity pill topped ...